Skip To Main Content
Jeff White on Muck Rack

Jeff White

As seen in: Medium, Forbes Advisor, Wiley Online Library, Memory Studies, PLOS ONE, Entrepreneur, American Inno, VentureBeat, National Post, Business 2 Community and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jeff

Contact Jeff, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

GLP-1 Receptor Agonists Reduce Colorectal Cancer Risk in IBD Populations

|
By Sherry Shen, Brandon Mancini, Jeff White
| ONCOLOGY journal Verified
Data from a large retrospective cohort study to be presented at the 2026 American Society of Clinical Oncology (ASCO) Breakthrough Meeting showed that GLP-1 receptor agonist (GLP-1 RA) use was significantly associated with lower colorectal cancer incidence among patients with inflammatory bowel disease (IBD), including those with comorbid type 2 diabetes (T2D).1,2 What were the key colorectal cancer findings in patients with IBD?
Open in Who Shared Issue with article?

EU Approves Enfortumab Vedotin/Pembrolizumab in Cisplatin-Ineligible MIBC

|
By Sherry Shen, Brandon Mancini, Jeff White
| ONCOLOGY journal Verified
The European Commission has approved enfortumab vedotin-ejfv (Padcev) in combination with pembrolizumab (Keytruda) for the treatment of adult patients with cisplatin-ineligible, resectable muscle invasive bladder cancer (MIBC), according to a news release from the developer, Astellas Pharma.1 Supporting the regulatory decision were data from the phase 3 KEYNOTE-905/EV-303 trial (NCT03924895), which evaluated the enfortumab-containing regimen against surgery alone among this MIBC population.2...
Open in Who Shared View Duplicates (2) Issue with article?

Efficacy of GLP-1 Receptor Agonists in Breast Cancer Populations

|
By Brandon Mancini, Jeff White, Patrick Borgen
| ONCOLOGY journal Verified
Recently published data in the journal ONCOLOGY focused on GLP-1 receptor agonist use for patients with breast cancer. Investigators aimed to study weight change among this population to determine if there was a benefit to its use. Sherry Shen, MD, assistant attending physician at Memorial Sloan Kettering Cancer Center, and the lead author on the study, spoke to CancerNetwork® about the results from the trial and how she is using that data to propel her research forward.
Open in Who Shared Issue with article?
See all 64 articles